Precision BioSciences, Inc.

NASDAQ:DTIL

Biotechnology

Healthcare
$7.10 +1.69%

+$0.11 today

Market cap
$198.34M
Beta
1.28
P/E (TTM)
-1.9
EPS (TTM)
-$3.47
52W Low $3.53High $8.82

Volume 0.37M

Average 0.31M

DTIL EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Precision BioSciences, Inc.NASDAQ: DTIL

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$17.49M, compared with -$19.51M a year earlier. Trailing-twelve-month EBITDA was -$40.42M.

Context

  • EBITDA amounted to 123.8% of revenue in FY2025, up 104.2 pp from a year earlier.
  • EBITDA increased in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 4 analysts of -$32.13M (+24.3%) for the fiscal year ending Dec 2026, a step up from the -413.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$17.49M-186.3% QoQ
Last fiscal yearDec 2025
-$42.43M-413.7% YoY
LTMMar 2026
-$40.42M-143.9% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.3%+5.8%-4.5 pp
1 year-413.7%+24.3%+438.0 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(42.43M) USD
Year-over-year change
-413.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How DTIL compares with its peers on the latest reported figures

  • DTIL's LTM Mar 2026 EBITDA of -$40.42M is the 3rd highest of the 7 companies compared; the peer median is -$92.66M.
  • Its year-over-year change of -143.9% is the 4th highest of 6, against a peer median of -1.3%.
  • EBITDA amounts to 89.7% of revenue for DTIL, versus a peer median of 304.0%.
DTIL Competitors Peer median
EBITDA for DTIL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
QTTBQ32 Bio Inc.LTM Mar 2026$22.15M +154.8%—41.2%
HRTXHeron Therapeutics, Inc.LTM Mar 2026-$24.12M -5355.8%—16.0%
DTILPrecision BioSciences, Inc.LTM Mar 2026-$40.42M -143.9%—89.7%
RNAAtrium Therapeutics, Inc.FY2025-$76.5M ——410.9%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026-$108.82M +2.8%——
ALECAlector, Inc.LTM Mar 2026-$116.42M -1.3%—632.1%
GOSSGossamer Bio, Inc.LTM Mar 2026-$168.81M -372.8%—304.0%
Peer median (excluding DTIL) -$92.66M-1.3%—304.0%

Competitors are the stored peer set for DTIL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue115.53M25.1M48.73M68.7M34.26M
Cost of Revenue00002.75M
Gross Profit115.53M25.1M48.73M68.7M31.51M
Gross Margin100.0%100.0%100.0%100.0%92.0%
Research & Development115.24M46.12M53.38M59.56M54.17M
Selling, General & Admin39.67M41.28M39.09M35.3M32.24M
Operating Expenses154.91M87.41M92.46M94.86M83.66M
Depreciation & Amortization10.2M9M8.26M4.58M2.75M
EBITDA(20.27M)(62.79M)(32.04M)13.53M(42.43M)
EBITDA Margin-17.5%-250.2%-65.8%19.7%-123.8%
Operating Income(39.38M)(62.31M)(43.74M)(26.16M)(52.15M)
Operating Margin-34.1%-248.3%-89.8%-38.1%-152.2%
Interest Income208K3.47M7.69M6.76M4.24M
Interest Expense132K1.11M2.23M1.78M1.42M
Other Income / Expenses8.77M(10.6M)1.21M33.33M5.54M
Income Before Tax(30.6M)(72.91M)(42.53M)7.17M(46.61M)
Pre-Tax Margin-26.5%-290.5%-87.3%10.4%-136.0%
Income Tax Expense00000
Net Income(30.6M)(111.64M)(61.32M)7.17M(46.61M)
Net Margin-26.5%-444.8%-125.8%10.4%-136.0%
EPS (Basic)(15.60)(38.10)(15.96)1.05(3.63)
EPS (Diluted)(15.60)(38.10)(15.96)1.04(3.63)
Weighted Avg Shares1.96M2.93M3.84M6.83M12.83M
Weighted Avg Shares (Diluted)1.96M2.93M3.84M6.88M12.83M

Precision BioSciences, Inc.

NASDAQ:DTIL

Intrinsic Alpha fair value

Locked

Current Price

$7.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.